Long Shortz with Neurizon Therapeutics: $5m raise and R&D rebate fuel ALS trial plans

Tylah Tully speaks with Neurizon Therapeutics (ASX:NUZ) managing director Dr Michael Thurn about the company’s latest funding success, regulatory milestones, and clinical development strategy.

Neurizon recently completed a $5 million institutional placement at $0.12 per share, backed by strong support from both new and existing investors.

Dr Thurn outlines how this strengthened balance sheet positions Neurizon for entry into the HEALY ALS Platform Trial in Q4 this year, while also supporting manufacturing, regulatory filings, and other preclinical programs.

Importantly, Neurizon secured an R&D tax incentive ruling through 2027, making both local and overseas R&D eligible for a 43.5% rebate, covering the cost of the Healy ALS trial and reducing risk and accelerating progress for lead candidate NUZ001.

Watch the video for more.

This video was developed in collaboration with Neurizon Therapeutics, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.